FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Исследования/New Study Explores Combination Peptide Therapy for Crohn’s Disease and Obesity
Назад в Научную Библиотеку

New Study Explores Combination Peptide Therapy for Crohn’s Disease and Obesity

May 25, 2026
Share
Развивающиеся Исследования

Основано на развивающихся исследованиях. Эти выводы обещающи, но требуют дальнейшей проверки.

О данном анализе

Эта статья является AI-опороченной сводкой последнего опубликованного новости или клинического испытания. Она предназначена для быстрого, доступного обзора для сообщества исследований Peptide. Для полной точности всегда обращайтесь к исходному источнику, указанному ниже.

New Study Explores Combination Peptide Therapy for Crohn’s Disease and Obesity

Researchers at Eli Lilly are launching a Phase 3 clinical trial to investigate the effectiveness of mirikizumab in conjunction with tirzepatide for patients suffering from moderately to severely active Crohn's disease (CD) along with obesity or overweight conditions. This study aims to provide critical insights into how these peptide therapies can be used together to improve patient outcomes.

Background

Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract, and it often coexists with other health issues like obesity. Traditional treatments for CD include immunosuppressants and biologics, but many patients require additional support due to persistent symptoms or side effects. Peptide-based therapies have gained traction in recent years due to their targeted approach and lower risk profile compared to conventional medications.

Mirikizumab is a humanized monoclonal antibody that inhibits interleukin-23 (IL-23), which plays a significant role in immune response regulation. It has shown promise in treating moderate-to-severe plaque psoriasis and ulcerative colitis, making it an interesting candidate for CD treatment as well.

Tirzepatide, on the other hand, is a glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It’s primarily used to manage type 2 diabetes and obesity by regulating appetite and metabolic processes.

The combination of these two peptides in the context of Crohn's disease and obesity represents a novel approach to managing complex comorbidities, potentially offering relief from both gastrointestinal inflammation and weight-related health issues simultaneously.

Key Details

This Phase 3 clinical trial will recruit adult participants who are suffering from moderately to severely active CD along with obesity or overweight conditions. The study’s primary objective is to assess the efficacy and safety of mirikizumab when used either alone or in combination with tirzepatide over a period of up to 61 weeks.

Participants will be randomly assigned to receive one of several treatment regimens, including different dosages and administration schedules for both peptides. Researchers will monitor various metrics such as disease activity scores, quality-of-life measures, and adverse event rates to gauge the overall impact of the treatments on patient health.

The study's findings could pave the way for new therapeutic options that address multiple aspects of Crohn’s disease management, particularly in patients who struggle with obesity or being overweight. By combining these two peptides, researchers hope to unlock synergistic benefits that neither treatment can achieve independently.

Key Takeaways

  • Novel Combination Therapy: The study will explore the potential of using mirikizumab and tirzepatide together for managing Crohn’s disease in conjunction with obesity or being overweight.
  • Targeted Approach: Peptide-based therapies like mirikizumab offer a more precise targeting mechanism compared to traditional broad-spectrum medications, potentially reducing side effects.
  • Long-Term Safety Evaluation: The study will assess the safety profile of these treatments over an extended period of up to 61 weeks, providing crucial data on long-term use and patient outcomes.
  • Impact on Quality of Life: By addressing multiple health concerns simultaneously, this combined approach could significantly improve patients' quality of life.

What This Means

This clinical trial represents a significant step forward in the development of peptide-based therapies for complex medical conditions like Crohn’s disease and obesity. If successful, it could lead to new treatment guidelines that incorporate these peptides into standard care protocols, benefiting millions of people around the world who struggle with chronic inflammatory diseases and weight management issues.

As research continues to uncover the benefits and limitations of various peptide treatments, studies like this one are vital for advancing our understanding and improving patient outcomes. The broader peptide community will closely follow the results of this trial as they provide valuable insights into the future direction of peptide therapy development and application.

---

Source: ClinicalTrials.gov — Published 2026-05-20

This article is for informational purposes only and does not constitute medical advice.

Примечание Редактора

Этот анализ был сгенерирован с использованием инструментов AI и проверен редакционной командой Peptide Contacts. Хотя мы стремимся к точности, содержание, сгенерированное AI, может содержать ошибки или пропуски. Мы призываем читателей проверить исходный источник полные детали, методология и данные.

Peptide Contacts предоставляет сводки научных исследований для информационных целей только. Это содержание не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед принятием каких-либо решений о здоровье.

Comments

Sign in to join the discussion

Эта статья была сгенерирована с использованием AI и может содержать неточности. Она предоставляется для информационных целей только и не является медицинским советом. Всегда проверяйте информацию в исходном источнике и консультируйтесь с квалифицированным медицинским специалистом перед принятием каких-либо решений о здоровье.